Autologous Anti-KK-LC-1 TCR-expressing T-cells

What is Autologous Anti-KK-LC-1 TCR-expressing T-cells?

Autologous anti-KK-LC-1 TCR-expressing T-cells are engineered T-lymphocytes expressing a T-cell receptor specific for the tumor-associated antigen KK-LC-1. Upon infusion, they target and bind KK-LC-1-expressing tumor cells, leading to T-cell activation and lysis. The therapy is being studied in gastric, breast, cervical, and lung cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type

Cell therapy (TCR-T)

Targets

Kita-Kyushu lung cancer antigen-1 (CT83) (antigen)

Mechanism

Kills target cells, directed at Kita-Kyushu lung cancer antigen-1 (CT83)

Therapy area

Oncology

In trials of

IOVA

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerCervical CancerGastric CancerLung Cancer

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT05483491

Updated Oct 3, 2026.